{
  "nctrialId": "HC-1964",
  "title": "A  Open-Label, Placebo-Controlled Multi-Center Study of HFR-841 (SGLT2 inhibitor) in Patients With Crohn's Disease",
  "officialTitle": "A  Open-Label, Placebo-Controlled Multi-Center Study of HFR-841 (SGLT2 inhibitor) in Patients With Crohn's Disease",
  "sponsor": "Dalhousie University",
  "indication": "Crohn's Disease",
  "phase": "Phase 4",
  "fileName": "HC-1964.json",
  "fileSize": 110802,
  "date": "2024-10-16",
  "completionDate": "2026-03-16",
  "drugName": "HFR-841 (SGLT2 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a  open-label, placebo-controlled multi-center study designed to evaluate the efficacy and safety of HFR-841 (SGLT2 inhibitor) in patients with Crohn's Disease. The study will enroll approximately 522 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 19-71 years\n- Confirmed diagnosis of Crohn's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1964"
}